News

A Promising New AIDS Drug Highlights The Dangers Of Price Controls
The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...
Publix Food Recall Update as 'Foreign Material' Found in Multiple Products
Publix has had to manage several recalls involving both meat and non-meat products since the start of the year.
US FDA approves KalVista's oral swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...
Wegovy and Zepbound prices fall, but access to the obesity drugs still isn’t guaranteed
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
Oregon Infants Sickened By Lead in Recalled Target Baby Food
MONDAY, July 7, 2025 — Two babies in Oregon got sick with lead poisoning after eating baby food from Target that was ...
Idaho lawmaker worked to legalize this drug. He was among the first to sell it
The drug gained a following in some circles for its supposed ability to treat COVID-19 safely, something all major medical ...
Palm Beach physician pioneering new advances in ALS and inflammatory disease treatment
Dr. Simrit Parmar, a Northwestern University-trained oncologist and research scientist, launched Cellenkos Inc., in 2016 to ...
STAT3h
Inside the staff exodus and tanking morale that threaten Makary’s FDA
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment
Mustang Bio shares more than quadrupled, to $5.23, after the company on Monday said the Food and Drug Administration granted orphan drug designation to Mustang for MB-101 for the treatment of ...
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable ...